**Panel Discussion/References**

Based upon review of the data in the noted references, the panel consensus supported the addition of entrectinib as a preferred first-line treatment option for *ROS1* rearrangement positive mNSCLC. The panel consensus supported a category 2A recommendation.

- See Submission for references.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

**Guideline Page and Request**

**NSCL-24, NSCL-I**

Panel request to review the data for entrectinib as a treatment option for *ROS1* rearrangement positive metastatic non-small cell lung cancer (mNSCLC).

External request: Submission from Genentech, requesting review of the data supporting the inclusion of entrectinib for the treatment of patients with *NTRK* fusion-positive mNSCLC and *ROS1*-positive mNSCLC.

**NSCL-26, NSCL-I**

Panel request to review the data for entrectinib as a treatment option for *NTRK* gene fusion positive mNSCLC.

External request: Submission from Genentech, requesting review of the data supporting the inclusion of entrectinib for the treatment of patients with *NTRK* fusion-positive mNSCLC and *ROS1*-positive mNSCLC.

Based upon review of the data in the noted references, the panel consensus supported the addition of entrectinib as a first-line/subsequent treatment option for *NTRK* gene fusion positive mNSCLC. The panel consensus supported a category 2A recommendation.

- See Submission for references.